EU Expands Indication for Gilead HIV Drug
May 28, 2003
On Tuesday, Gilead Science announced it has received authorization from the European Union to expand the indication of its HIV drug Viread in all 15 EU states. With the expansion, Viread is approved for use in combination with other drugs to prevent the duplication of HIV in patients initiating antiretroviral therapy as well as in previously treated patients. The EU's Committee for Proprietary Medicinal Products and the Scientific Committee of the European Medicines Evaluation Agency gave the marketing authorization based on a 49-week study of 600 treatment-naive HIV-infected patients, Gilead said.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.